Article Text

Download PDFPDF
Economic Considerations on the Follow-Up Practice in Gynecologic Cancers: Few Lights and Many Shadows From a Literature Review
  1. Eva Pagano, MSc*,
  2. Simona Sobrero, MD,
  3. Camilla Cavallero, MD,
  4. Paolo Zola, MD and
  5. Giovannino Ciccone, MD, PhD*
  1. *Unit of Cancer Epidemiology, “Città della Salute e della Scienza, Turin” Hospital–University of Turin and CPO Piemonte, Torino, Italy; and
  2. Department of Surgical Sciences, University of Turin, Torino, Italy.
  1. Address correspondence and reprint requests to Eva Pagano, MSc, Unit of Cancer Epidemiology, University of Torino, “Città della Salute e della Scienza di Torino” Hospital, Via Santena 7, 10126, Torino, Italy. E-mail: eva.pagano{at}cpo.it.

Abstract

Objective The aim of this review was to analyze the existing literature on the cost of follow-up in gynecology oncology.

Methods/materials We performed a literature search in Medline and NHS CRD (University of Oxford) databases. Research strings were mainly based on MESH terms referring to economic studies and to neoplasms follow-up/aftercare and cancer recurrences. Two independent searches were performed for ovarian neoplasm and uterine neoplasm. Some studies were also identified among the references of the selected articles. Potentially relevant studies were identified based on the title and abstract by 2 independent readers.

Results Finally, the reviewing process selected 2 studies on gynecologic cancers in general, including uterine and ovarian cancers, 3 specific on ovarian cancer, 7 on endometrium, and 9 on cervix. The identified economic literature on economic evaluation of gynecologic cancer follow-up procedures showed to be based on weak evidence of effectiveness and to lack formal methodological approaches. In general, such literature is quite recent, relies on small sample observational studies, and suffers from a lack of financial support.

Conclusions There are few available lights in economic considerations on gynecologic cancer follow-up, represented by all the published studies, and many shadows that require to be clarified by properly designed randomized trials including cost-effectiveness analysis.

  • Follow-up
  • Economic evaluation
  • Cost analysis
  • Uterine cancer
  • Ovarian cancer

Statistics from Altmetric.com

Footnotes

  • This review has been carried out by the authors as part of their contribution to the ESGO State of the art conference 2014, held in Turin.

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.